NASH Is A Massive Market
Ultimately, breaking into a large market with a clear medical need is the goal of clinical stage biotechnology companies like HEPA. In this particular case, the market potential is incredible.
While no one knows exactly what the market for NASH and other liver diseases are, experts at Credit Suisse suggest that the market could be worth $20 billion by 2030. RBC Capital Markets says that the market will grow to be worth $7 billion by the year 2026.
Regardless of whose predictions are closer to the mark, it’s clear to see that the market for NASH is massive. It’s also worth mentioning that there are other liver diseases outside of NASH that CRV431 may be effective in treating. This only expands the market opportunity.
While it would be foolish to say that a company will take 100% of any market, HEPA doesn’t have to. With a market cap of about $13 million, tapping into even a small percentage of this market would lead to substantial growth in value.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Click below to continue reading!